Advertisement

Ads Placeholder
Loading...

NewAmsterdam Pharma Company N.V.

NAMS•NASDAQ
Healthcare
Biotechnology
$32.99
$0.18(0.55%)
U.S. Market opens in 25h 24m

NewAmsterdam Pharma Company N.V. (NAMS) Stock Overview

Explore NewAmsterdam Pharma Company N.V.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap3.8B
P/E Ratio-18.52
EPS (TTM)$-1.72
ROE-0.27%
Fundamental Analysis

AI Price Forecasts

1 Month$30.67
3 Months$33.35
1 Year Target$39.01

NAMS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of NewAmsterdam Pharma Company N.V. (NAMS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 56.58, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $39.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -18.52 and a market capitalization of 3.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
0.55%
5-Day Change
6.56%
1-Month Change
8.48%
3-Month Change
-6.28%
6-Month Change
7.56%
Year-to-Date (YTD) Change
-6.28%
1-Year Change
83.28%
3-Year Change
143.83%
5-Year Change
234.25%
All-Time (Max) Change
210.87%

Contact Information

https://www.newamsterdampharma.com
31 35 206 2971
Gooimeer 2-35, Naarden, NaN, 1411 DC

Company Facts

680 Employees
IPO DateFeb 9, 2021
CountryNL
Actively Trading

Frequently Asked Questions